Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISOTOVE: IP Scintigraphy for Chemotherapy Distribution in Ovarian Cancer
NCT02667925Withdrawn
- Sponsor
- Centre Jean Perrin
- Start
- Mar 2016
- Primary completion
- Sep 2016
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Open-label, single-arm trial of technetium (99mTc) rhenium sulfide colloid in ovarian cancer, sponsored by Centre Jean Perrin. Primary endpoint: Intensity of fixation of the solvent in the intraperitoneal cavity at 18 weeks. Planned start Mar 2016; status: withdrawn.
02
Drugs
technetium (99mTc) rhenium sulfide colloid
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02667925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667925.